Priapism

Topic Overview

Summary

Priapism is a persistent, pathological erection of the penis lasting longer than 4 hours, unrelated to sexual stimulation or desire. [1] It represents a true urological emergency—particularly ischaemic priapism—where delayed treatment beyond 4-6 hours leads to irreversible smooth muscle necrosis and permanent erectile dysfunction. [2] There are three main types: ischaemic (low-flow), the most common and urgent form characterized by painful, rigid corpora cavernosa with venous outflow obstruction; non-ischaemic (high-flow), a rare, painless condition caused by arterial-lacunar fistula following perineal trauma; and stuttering (recurrent ischaemic), intermittent episodes that progressively increase in duration and severity. [1,3]

Ischaemic priapism accounts for > 95% of cases and is a compartment syndrome of the penis. [4] The aetiology is diverse: sickle cell disease (most common in children, affecting up to 40% over their lifetime), intracavernosal vasoactive injections, medications (antipsychotics, trazodone), recreational drugs (cocaine), haematological malignancies, and idiopathic causes (up to 30%). [5,6] Blood gas analysis from corporal aspirate is the definitive diagnostic test: dark blood with pO₂ less than 30 mmHg, pCO₂ > 60 mmHg, and pH less than 7.25 confirms ischaemia. [7]

Immediate management of ischaemic priapism includes analgesia, corporal aspiration (19G butterfly, lateral approach), and intracavernosal phenylephrine injection (100-500 mcg diluted, repeated every 3-5 minutes with cardiovascular monitoring). [1,8] If medical therapy fails within 1 hour, surgical shunting is required—starting with distal shunts (Winter's or Al-Ghorab procedures), escalating to proximal shunts if necessary. [9] Time is tissue: erectile function preservation is > 90% if treated within 12 hours, drops to 50% at 12-24 hours, and falls below 10% after 24 hours. [10]

Key Facts

• Definition: Penile erection persisting > 4 hours, independent of sexual stimulation [1]
• Ischaemic (low-flow): Painful, rigid, emergency—compartment syndrome of penis [4]
• Non-ischaemic (high-flow): Painless, tumescent, non-urgent—arterial fistula from trauma [3]
• Stuttering: Recurrent episodes, usually in sickle cell disease; risk factor for major episode [11]
• Common causes: Sickle cell (35-42% lifetime risk), intracavernosal injections, antipsychotics, trazodone, cocaine [5,12]
• Blood gas differentiation: Ischaemic (pO₂ less than 30, pH less than 7.25) vs non-ischaemic (pO₂ > 90, pH > 7.35) [7]
• Treatment window: less than 4-6 hours optimal; > 12 hours = significant smooth muscle necrosis [2,10]
• First-line treatment: Aspiration + phenylephrine intracavernosal injection (α-agonist) [8]
• Surgical options: Distal shunt (Winter, Al-Ghorab) → proximal shunt (Quackels, Grayhack) [9]
• Outcome: Erectile dysfunction in 90% if treatment delayed > 24 hours [10]

Clinical Pearls

Ischaemic priapism = compartment syndrome of the penis—treat within 4-6 hours to prevent irreversible smooth muscle necrosis and fibrosis.

Sickle cell disease is the commonest cause in children and adolescents—up to 40% lifetime prevalence, often presenting with stuttering episodes before a major event. [5,12]

Blood gas from corporal aspirate is diagnostic: Dark blood + acidosis (pO₂ less than 30, pH less than 7.25) = ischaemic; bright red blood (pO₂ > 90) = non-ischaemic. [7]

Glans and corpus spongiosum are typically spared in ischaemic priapism due to separate venous drainage—a key clinical differentiator.

Phenylephrine is safer than adrenaline for intracavernosal injection (pure α₁-agonist vs α+β effects); monitor blood pressure and heart rate during administration. [8]

Do not aspirate non-ischaemic priapism—it is not an emergency and may resolve spontaneously; selective arterial embolisation is definitive if needed. [3]

Why This Matters Clinically

Ischaemic priapism is one of the few true urological emergencies where delay directly correlates with permanent disability. Every hour beyond 4-6 hours increases the risk of irreversible corporal fibrosis and lifelong erectile dysfunction. [2,10] Emergency physicians, urologists, and haematologists must recognize priapism immediately, differentiate ischaemic from non-ischaemic types using blood gas analysis, and initiate treatment without delay. In sickle cell patients, priapism is a frequent, devastating complication requiring multidisciplinary care including exchange transfusion and preventive strategies. [12,13] Failure to treat promptly results not only in loss of erectile function but also significant psychological morbidity and medicolegal consequences.

---

Visual Summary

Visual assets to be added:

• Priapism classification algorithm (ischaemic vs non-ischaemic vs stuttering)
• Blood gas interpretation table with values and colours
• Corporal aspiration and phenylephrine injection technique (lateral approach, 19G butterfly)
• Surgical shunt procedures diagram (Winter, Al-Ghorab, Quackels)
• Management algorithm: aspiration → phenylephrine → distal shunt → proximal shunt
• Time-to-treatment vs erectile dysfunction outcome graph
• Ischaemic vs non-ischaemic comparison table

---

Epidemiology

Incidence and Prevalence

Priapism has an overall incidence of 1.5 per 100,000 males per year in the general population. [14] However, this varies dramatically by age and underlying condition:

• General population: 1.5/100,000 annually [14]
• Sickle cell disease (SCD): 35-42% lifetime prevalence; annual incidence 3-4% [5,12]
• Bimodal age distribution: Peak in children aged 5-10 years (SCD-related) and adults aged 20-50 years (drug-related, intracavernosal injections) [14]

Exam Detail: Priapism in sickle cell disease demonstrates a clear age-dependent pattern: stuttering episodes often begin in adolescence, with the first major ischaemic event typically occurring in early adulthood. Data from the Cooperative Study of Sickle Cell Disease showed that by age 20, 89% of males with SCD who develop priapism have already experienced at least one episode. [12]

Demographics and Risk Factors

Geographic and Ethnic Variation

Priapism incidence is significantly higher in populations with elevated prevalence of sickle cell disease—particularly Sub-Saharan Africa, Mediterranean regions, Middle East, and Afro-Caribbean communities. [5] In the United States, African American males have a 13-fold higher incidence compared to Caucasian males, predominantly driven by sickle cell trait and disease. [14]

---

Aetiology and Pathophysiology

Molecular and Cellular Mechanisms

Ischaemic (Low-Flow) Priapism

Ischaemic priapism is fundamentally a failure of penile detumescence due to venous outflow obstruction, leading to compartment syndrome. [4]

Pathophysiological Cascade:

1. Venous Outflow Obstruction

   • Veno-occlusive dysfunction (dysfunctional smooth muscle relaxation)
   • Sludging of blood (sickle cell disease, hyperviscosity syndromes)
   • Mechanical obstruction (leukaemic infiltration, malignant priapism) [5,14]

2. Blood Stasis in Corpora Cavernosa

   • Lack of fresh arterial inflow → progressive hypoxia
   • Accumulation of metabolic waste (lactic acid, CO₂)
   • Continued smooth muscle relaxation traps blood [4]

3. Progressive Hypoxia and Acidosis

   • pO₂ falls from normal ~40 mmHg to less than 30 mmHg [7]
   • pH falls from ~7.40 to less than 7.25 (lactic acidosis) [7]
   • pCO₂ rises above 60 mmHg [7]

4. Smooth Muscle and Endothelial Damage

   • Hypoxia → mitochondrial dysfunction → ATP depletion
   • Calcium overload → smooth muscle cell death (necrosis)
   • Endothelial injury → interstitial oedema → further compression [2]

5. Fibrosis and Permanent Erectile Dysfunction

   • Smooth muscle replaced by collagen deposition (fibrosis)
   • Loss of corporal compliance → veno-occlusive dysfunction
   • Irreversible after 24-48 hours [2,10]

Exam Detail: Molecular Pathways in Sickle Cell Priapism:

Sickle cell priapism has a distinct molecular basis. Chronic haemolysis releases free haemoglobin, which scavenges nitric oxide (NO), a key mediator of smooth muscle relaxation. Reduced NO bioavailability leads to dysregulated PDE5 activity, decreased cGMP, and impaired detumescence. Additionally, sickling is exacerbated by acidosis, hypoxia, and dehydration—all present in the ischaemic corporal environment—creating a vicious cycle. [5,13]

The adenosine hypothesis suggests that adenosine accumulation (from ATP degradation during ischaemia) acts on A₂B receptors, causing persistent smooth muscle relaxation and priapism. This has therapeutic implications: A₂B receptor antagonists are under investigation for prevention. [13]

Non-Ischaemic (High-Flow) Priapism

Non-ischaemic priapism arises from unregulated arterial inflow without venous obstruction. [3]

Pathophysiological Sequence:

1. Arterial-Lacunar Fistula Formation

   • Usually follows blunt perineal trauma (straddle injury, coital injury)
   • Rupture of cavernosal artery or helicine arteriole
   • Direct shunting of arterial blood into lacunar spaces [3]

2. Unregulated High-Flow Arterial Inflow

   • Bypasses normal neurovascular control
   • Continuous influx of oxygenated blood (pO₂ > 90 mmHg) [7]
   • Venous drainage remains intact—no ischaemia

3. Partial Tumescence Without Ischaemia

   • Corpora are tumescent but not fully rigid
   • No pain (no ischaemia, no compartment pressure)
   • No tissue damage—smooth muscle remains viable [3]

Stuttering (Recurrent Ischaemic) Priapism

Stuttering priapism is characterized by self-limiting, recurrent episodes of ischaemic priapism, each lasting less than 3-4 hours. [11] It is almost exclusively seen in sickle cell disease. Over time, episodes increase in frequency and duration, ultimately culminating in a major, sustained ischaemic event. [11,12] The underlying mechanism is the same as ischaemic priapism but with partial, spontaneous resolution—likely due to transient restoration of venous drainage or shifts in corporal smooth muscle tone.

Causes by Category

Clinical Pearl: Drug-Induced Priapism: Mechanism by Class

• Antipsychotics: α₁-adrenergic receptor blockade → loss of detumescence signal
• Trazodone: α₁-antagonism; risk 1/6,000 patients but can occur with therapeutic dosing
• PDE5 inhibitors (sildenafil, tadalafil): Rare; usually in combination with other risk factors
• Cocaine: Exact mechanism unclear; likely combination of α-blockade and endothelial injury [15]

---

Clinical Presentation

Ischaemic (Low-Flow) Priapism

Ischaemic priapism is the classic emergency presentation. [1,4]

Symptoms:

• Painful erection (often severe, progressive pain)
• Duration > 4 hours (critical threshold for intervention)
• Erection unrelated to sexual activity or desire
• Inability to achieve detumescence despite attempts (cold compresses, ejaculation)

Signs:

• Fully rigid corpora cavernosa (bilaterally)
• Glans and corpus spongiosum soft (spared due to separate venous drainage)
• Tenderness on palpation (compartment syndrome)
• Dark, deoxygenated blood on aspiration

Key Discriminators:

• Pain (vs painless in non-ischaemic)
• Full rigidity (vs partial tumescence in non-ischaemic)
• Dark aspirate with acidosis [7]

Non-Ischaemic (High-Flow) Priapism

Non-ischaemic priapism is rare (~5% of cases) and not an emergency. [3]

Symptoms:

• Painless or minimal discomfort
• Partial tumescence (not fully rigid; may wax and wane)
• Often follows history of perineal trauma days to weeks prior (straddle injury, coital trauma)

Signs:

• Partially erect, fluctuant corpora cavernosa
• Glans may be partially tumescent (unlike ischaemic)
• Bright red, well-oxygenated blood on aspiration
• No tenderness

Key Discriminators:

• History of trauma
• Painless, partial erection
• Bright red aspirate with pO₂ > 90 mmHg [7]

Stuttering (Recurrent) Priapism

Stuttering priapism presents as recurrent, self-limiting episodes of painful erections. [11]

Characteristics:

• Episodes last less than 3-4 hours, resolving spontaneously
• Typically occur at night or early morning (diurnal variation; REM sleep association)
• Increasing frequency over time
• Strong association with sickle cell disease [11,12]
• Risk factor for major, prolonged ischaemic event

Patients often describe waking with a painful erection that resolves after urination, physical activity, or cold shower—only to recur nights later with increasing frequency.

Red Flags

---

Clinical Examination

Focused Penile Examination

Inspection:

• Erect penis: Assess duration (ask patient when it started)
• Note angle of erection (usually upright in ischaemic; may be semi-erect, variable angle in non-ischaemic)
• Look for signs of trauma, bruising, or skin changes

Palpation:

• Rigidity: Fully rigid corpora cavernosa (ischaemic) vs fluctuant, partially tumescent (non-ischaemic)
• Glans and corpus spongiosum: Should be soft in ischaemic priapism (key sign); may be partially tumescent in non-ischaemic
• Tenderness: Tender in ischaemic (compartment syndrome); non-tender in non-ischaemic
• Temperature: Normal or cool (not a reliable sign)

Distinguishing Features:

Perineal and Scrotal Examination

• Perineal bruising or trauma: Suggests non-ischaemic priapism (arterial injury) [3]
• Scrotal examination: Normal testes; check for masses (rare: testicular tumour with metastases)

Systemic Examination

• Sickle cell crisis: Fever, jaundice, bone pain, splenomegaly [5]
• Signs of leukaemia or haematological malignancy: Lymphadenopathy, hepatosplenomegaly, pallor, bruising [14]
• Neurological examination: If spinal cause suspected (saddle anaesthesia, lower limb weakness)

Clinical Pearl: The "Soft Glans Sign" is pathognomonic for ischaemic priapism. Because the glans and corpus spongiosum have separate venous drainage (via the dorsal and deep dorsal veins), they are spared in low-flow priapism. This creates the characteristic "rigid shaft, soft tip" appearance that immediately differentiates ischaemic from non-ischaemic priapism.

---

Investigations

Cavernosal Blood Gas — Gold Standard Diagnostic Test

Corporal aspiration and blood gas analysis is the definitive investigation to differentiate ischaemic from non-ischaemic priapism. [7]

Technique:

1. Prepare: 19-21G butterfly needle, syringe, heparinised blood gas syringe
2. Site: Lateral aspect of corpus cavernosum (avoid dorsal neurovascular bundle and ventral urethra)
3. Aspire 1-2 mL blood
4. Immediate blood gas analysis (or compare colour visually if BGA unavailable)

Interpretation:

Exam Detail: Physiology of Corporal Blood Gas:

The normal flaccid penis has low oxygen tension (pO₂ ~30-40 mmHg) due to minimal arterial inflow and sluggish venous drainage. During erection, arterial inflow increases dramatically, raising pO₂ to ~90-100 mmHg. In ischaemic priapism, venous outflow obstruction with minimal arterial inflow causes severe hypoxia (pO₂ less than 30 mmHg) and lactic acidosis (pH less than 7.25). In non-ischaemic priapism, unrestricted arterial inflow maintains high pO₂ (> 90 mmHg) despite persistent erection. [7]

Haematological Investigations

Indicated to identify underlying causes, particularly in first-episode or idiopathic priapism:

• Full blood count (FBC): Anaemia, leucocytosis (leukaemia), polycythaemia
• Reticulocyte count: Elevated in haemolytic anaemias (sickle cell)
• Blood film: Sickle cells, blast cells (leukaemia)
• Sickle cell screen/Hb electrophoresis: Mandatory if ethnicity or history suggestive [5,12]
• Coagulation screen: Rarely contributory unless malignancy suspected

Imaging

Doppler Ultrasound (Penile)

Indication: Suspected non-ischaemic priapism (to identify arterial fistula) [3]

Findings:

• Non-ischaemic: Turbulent, high-velocity arterial flow in corpus cavernosum; visible fistula or pseudoaneurysm
• Ischaemic: Minimal or absent flow

Note: Doppler is not required for ischaemic priapism diagnosis (blood gas is sufficient) and should not delay treatment.

Selective Pudendal Arteriography

Indication: Definitive localisation of arterial fistula prior to selective embolisation in non-ischaemic priapism [3]

Findings:

• Contrast extravasation at fistula site
• Arterial-lacunar communication

This is therapeutic as well as diagnostic: embolisation coils can be deployed during the procedure.

Toxicology Screen

If history suggests recreational drug use (particularly cocaine), a urine toxicology screen may identify the precipitant. [15]

Special Investigations

• Cavernosography (rare): Contrast injection into corpora to visualize venous drainage; rarely performed now
• MRI pelvis (if malignancy suspected): To assess for pelvic masses causing venous compression

---

Classification and Staging

Classification by Type

Duration-Based Staging (Ischaemic Priapism)

Duration correlates directly with smooth muscle damage and erectile dysfunction risk. [2,10]

Exam Detail: Histopathological Changes Over Time:

• 0-4 hours: Oedema, minimal structural change
• 12 hours: Interstitial oedema, trabeculae thickening, early smooth muscle necrosis
• 24 hours: Extensive smooth muscle necrosis, thrombosis of lacunar spaces
• 48 hours: Fibroblast infiltration, collagen deposition (fibrosis initiation)
• > 1 week: Dense fibrous tissue replacement, complete loss of erectile tissue architecture [2]

This progression underscores the critical nature of the 4-6 hour window for intervention.

---

Differential Diagnosis

Conditions Mimicking Priapism

The key differentiator is persistent erection > 4 hours unrelated to sexual stimulation. Corporal blood gas confirms priapism type if doubt exists.

---

Management

General Principles

Ischaemic priapism is a time-critical emergency. Goals are:

1. Rapid detumescence (within 4-6 hours of onset) [2]
2. Preservation of erectile function
3. Minimise pain and distress
4. Treat underlying cause (e.g., sickle cell crisis)

Non-ischaemic priapism is not an emergency and can be observed or treated electively. [3]

Ischaemic Priapism — Stepwise Management Algorithm

---

Step 1: Analgesia

• Oral/IV analgesia: Paracetamol, NSAIDs, opioids (morphine, oxycodone) as required
• Penile block (dorsal nerve block): Local anaesthetic (e.g., 1% lidocaine 10 mL) infiltrated at base of penis, bilaterally, sparing dorsal neurovascular bundle [1]
  • Provides excellent analgesia for aspiration and phenylephrine injection
  • Does not interfere with treatment efficacy

---

Step 2: Corporal Aspiration

Objective: Remove stagnant, deoxygenated blood to reduce compartment pressure and allow arterial inflow. [1,8]

Technique:

1. Patient position: Supine
2. Preparation: Sterile technique; penile block for analgesia
3. Needle: 19-21G butterfly needle or cannula
4. Site: Lateral aspect of proximal or mid-shaft corpus cavernosum
   • Avoid: Dorsal neurovascular bundle (dorsally) and urethra (ventrally)
   • Entry at 3 o'clock or 9 o'clock position is safest
5. Aspiration: Insert needle perpendicular to skin; aspirate 20-100 mL dark blood until bright red blood appears
   • Can irrigate with normal saline (20-50 mL) to flush acidotic blood if aspiration inadequate

Endpoint: Detumescence or appearance of bright red blood (indicating restored arterial inflow)

Clinical Pearl: "Milk the penis" during aspiration by applying pressure from base to tip to facilitate drainage. This manual compression aids venous outflow and is safe.

---

Step 3: Intracavernosal Phenylephrine Injection

If aspiration alone fails to achieve detumescence, proceed immediately to phenylephrine injection. [8]

Pharmacology:

• Phenylephrine: Selective α₁-adrenergic agonist → smooth muscle contraction → detumescence
• Preferred over adrenaline (epinephrine): Pure α₁ effects; no β-agonism (less cardiac risk)
• Dose: 100-500 mcg diluted in normal saline (e.g., 1 mg phenylephrine in 20 mL saline = 50 mcg/mL)

Technique:

1. Dilute phenylephrine: 1 mg in 10-20 mL normal saline
2. Inject 0.5-1 mL (50-200 mcg) intracavernosally (same site as aspiration)
3. Wait 3-5 minutes; assess for detumescence
4. Repeat every 3-5 minutes if no response
5. Maximum: Continue for up to 1 hour; cumulative dose rarely exceeds 1 mg [1,8]

Monitoring:

• Blood pressure and heart rate every 5 minutes during injection
• Watch for hypertension, reflex bradycardia, palpitations, headache (α₁ effects) [8]
• Particularly important in elderly, cardiovascular disease, or on β-blockers

Endpoint: Detumescence (flaccidity)

Exam Detail: Phenylephrine Evidence:

The hemodynamic effects of intracavernosal phenylephrine were studied in 22 patients with ischaemic priapism: mean systolic BP increased by 10-15 mmHg transiently, with no clinically significant arrhythmias or cardiovascular events. Success rate was 75% with aspiration + phenylephrine when initiated within 12 hours. [8] This supports its safety and efficacy as first-line medical therapy.

---

Step 4: Surgical Shunt (If Medical Therapy Fails)

If aspiration and phenylephrine fail after 1 hour (or patient presents > 24-48 hours with established fibrosis), surgical shunting is required. [9]

Principle: Create a fistula between ischaemic corpora cavernosa and the glans (distal shunt) or corpus spongiosum/venous system (proximal shunt) to allow venous drainage.

---

Distal Shunts (First-Line Surgical)

Indications: First-line surgical intervention when medical therapy fails [9]

1. Winter Shunt (Percutaneous Distal Shunt)

• Technique: Insert large-bore needle (e.g., Tru-Cut biopsy needle) through glans into corpus cavernosum; create multiple fistulae
• Advantage: Percutaneous, quick, bedside procedure
• Success: 60-70% [9]

2. Al-Ghorab Shunt (Open Distal Shunt)

• Technique: Circumcoronal or midline glans incision; excise 1-2 cm disc of tunica albuginea bilaterally at glans-corporal junction
• Advantage: Larger, more reliable fistula than Winter; higher success rate
• Success: 70-80% [9]
• Disadvantage: Open procedure; glans scarring

3. T-Shunt (Ebbehoj Modification)

• Technique: Similar to Al-Ghorab but T-shaped incision in tunica albuginea + evacuation of clots
• Advantage: Combines shunt + clot removal
• Success: Similar to Al-Ghorab [9]

---

Proximal Shunts (If Distal Shunts Fail)

Indications: Failure of distal shunts; prolonged priapism (> 48-72 hours) with extensive clotting [9]

1. Quackels Shunt

• Technique: Perineal incision; create fistula between corpora cavernosa and corpus spongiosum
• Advantage: Bypasses entire corporal length
• Disadvantage: Invasive; risk of urethral injury

2. Grayhack Shunt (Saphenous Vein Shunt)

• Technique: Anastomose saphenous vein graft between corpus cavernosum and femoral/saphenous vein
• Advantage: Large-bore venous drainage
• Disadvantage: Complex; vascular surgery expertise required

Success Rates: Proximal shunts have variable success (50-70%) and higher complication rates. [9]

---

Step 5: Penile Prosthesis (Immediate or Delayed)

Indications:

• Immediate (acute): Priapism > 48-72 hours with established fibrosis; shunts likely to fail [16]
• Delayed (chronic): Persistent erectile dysfunction post-priapism (90% if > 24 hours) [10,16]

Immediate Prosthesis:

• Emerging evidence suggests early prosthesis insertion (within 2 weeks) offers superior outcomes compared to delayed insertion (> 3 months) in refractory ischaemic priapism. [16]
• Allows immediate detumescence, prevents further fibrosis, and restores erectile function
• Technically challenging due to fibrosis; requires experienced surgeon (corporotomy, dilation, possible Shaeer technique for fibrous excavation) [16]

Delayed Prosthesis:

• For patients with established ED post-priapism
• Standard inflatable or malleable prosthesis insertion
• More fibrosis makes surgery difficult; higher risk of complications

---

Non-Ischaemic Priapism — Conservative and Selective Embolisation

Management:

1. Observation: Many cases resolve spontaneously over weeks to months [3]
2. Selective arterial embolisation: If persistent or bothersome
   • Pudendal arteriography to localise fistula
   • Deploy embolisation coils or gel foam to occlude fistula
   • Success rate ~75%; low risk of ED (preserves overall penile blood supply) [3]
3. Surgical ligation: Rarely required (open ligation of fistula)

Do NOT aspirate or inject phenylephrine in non-ischaemic priapism—it is ineffective and unnecessary. [3]

---

Sickle Cell-Specific Management

Priapism in sickle cell disease requires haematology involvement and tailored therapy. [12,13]

Acute Episode:

1. Analgesia: Opioids; aggressive pain control
2. Hydration: IV fluids (avoid overhydration; aim euvolaemia)
3. Oxygen: If hypoxic (does not reverse sickling in priapism but supports general oxygenation)
4. Aspiration + Phenylephrine: As per standard ischaemic priapism protocol [1,8]
5. Exchange Transfusion: Consider if:
   • Refractory to aspiration + phenylephrine
   • Recurrent or prolonged priapism (> 12 hours)
   • Target HbS less than 30% [13]
   • Evidence supports safety and efficacy, particularly in refractory cases [13]

Stuttering Priapism Prevention:

• Oral pseudoephedrine (α-agonist): 30-60 mg nightly or as needed before bed [11]
• Hydroxyurea: Increases HbF, reduces sickling; reduces priapism frequency [12,13]
• GnRH agonists (e.g., leuprolide): Androgen suppression; used in refractory cases (side effects: hypogonadism, osteoporosis)
• Regular automated red cell exchange (RCE) transfusion: For severe, recurrent stuttering priapism unresponsive to medical therapy [13]

Exam Detail: Exchange Transfusion Evidence:

A study of 14 sickle cell patients with priapism treated with exchange transfusion showed detumescence in 86% (12/14) with no adverse events. The mean time to detumescence was 8 hours. Patients with stuttering priapism on prophylactic exchange had significant reduction in episode frequency. [13] However, exchange transfusion is not first-line—reserve for refractory cases due to resource intensity and transfusion risks.

---

Special Populations

Paediatric Priapism

• Predominantly sickle cell-related [5]
• Same management principles apply (aspiration + phenylephrine)
• Psychological support critical: Priapism is distressing and embarrassing for children/adolescents
• Early haematology involvement for long-term SCD management

Cocaine-Induced Priapism

• Increasingly recognised cause [15]
• Same ischaemic priapism protocol
• Aspiration + phenylephrine often successful
• Avoid β-blockers (unopposed α-stimulation in acute cocaine toxicity)
• Manage concurrent cardiovascular effects (hypertension, tachycardia, arrhythmias)

---

Complications

Complications of Ischaemic Priapism Itself

Complications of Treatment

---

Prognosis and Outcomes

Erectile Function After Ischaemic Priapism

Duration is the single strongest predictor of erectile dysfunction risk. [10]

Exam Detail: Long-Term Outcomes Study:

A retrospective review of 230 patients with ischaemic priapism found that spontaneous return of erectile function occurred in:

• 85% if treated less than 12 hours
• 45% if treated 12-24 hours
• 8% if treated > 24 hours

Of those with ED, 70% eventually underwent penile prosthesis insertion (mean 18 months post-priapism). Earlier prosthesis insertion (less than 2 weeks) was associated with better patient satisfaction and fewer surgical complications compared to delayed insertion (> 3 months). [16]

Non-Ischaemic Priapism

• Excellent prognosis: ED risk less than 5% [3]
• Spontaneous resolution in ~60% within 6-12 months
• Selective embolisation: 75% success, low ED risk

Stuttering Priapism

• High risk of progressing to major, sustained ischaemic event [11]
• Preventive strategies (pseudoephedrine, hydroxyurea, exchange transfusion) reduce episode frequency and severity [11,13]
• Chronic psychological burden (nocturnal episodes, fear of progression)

---

Prevention and Counselling

Primary Prevention (Sickle Cell Patients)

• Hydroxyurea: Increases HbF; reduces sickling and priapism episodes [12,13]
• Adequate hydration: Avoid dehydration (triggers sickling)
• Avoid known triggers: Excessive alcohol, recreational drugs, extreme cold
• Patient education: Recognise early symptoms (stuttering episodes); seek early treatment

Secondary Prevention (After First Episode)

• Pseudoephedrine: 30-60 mg nightly (α-agonist; promotes detumescence) [11]
• Self-injection therapy education: Teach patients to inject phenylephrine at home for stuttering episodes (specialist-supervised; not universal practice)
• Regular haematology follow-up (sickle cell patients)
• Automated RCE transfusion: For refractory stuttering priapism [13]

Counselling Post-Priapism

Immediate (during treatment):

• Explain procedure (aspiration, phenylephrine, potential shunt)
• Discuss ED risk based on duration
• Realistic expectations: If > 24 hours, ED is likely

Follow-Up (6-12 weeks):

• Assess erectile function
• Offer PDE5 inhibitors (sildenafil, tadalafil) trial
• Vacuum erection devices, intracavernosal injections (if tolerated)
• Referral to sexual medicine/urology for prosthesis discussion if refractory ED [16]

---

Examination Focus (Viva Questions and Model Answers)

Question 1: How do you differentiate ischaemic from non-ischaemic priapism?

Model Answer:

"The key differentiators are clinical features and corporal blood gas analysis.

Clinically:

• Ischaemic priapism presents with a painful, fully rigid erection with a soft glans. The patient describes progressive pain over hours.
• Non-ischaemic priapism is painless, partially tumescent, and often has a history of perineal trauma days to weeks earlier.

Investigations:

• Corporal blood gas is the gold standard. Aspirate blood from the lateral corpus cavernosum:
  • "Ischaemic: Dark blood, pO₂ less than 30 mmHg, pCO₂ > 60 mmHg, pH less than 7.25 (acidosis due to hypoxia)."
  • "Non-ischaemic: Bright red blood, pO₂ > 90 mmHg, pH > 7.35 (well-oxygenated arterial blood from fistula)."

This distinction is critical because ischaemic priapism is an emergency requiring immediate aspiration and phenylephrine, whereas non-ischaemic priapism can be observed or treated electively with embolisation."

---

Question 2: Walk me through your immediate management of a 28-year-old with painful priapism for 8 hours.

Model Answer:

"This is an ischaemic priapism emergency. My priorities are rapid detumescence and erectile function preservation.

Immediate Steps:

1. Analgesia: IV morphine and/or penile dorsal nerve block (1% lidocaine 10 mL bilaterally).

2. Corporal aspiration:

   • Use a 19G butterfly needle, lateral approach (3 or 9 o'clock position) to avoid dorsal neurovascular bundle and urethra.
   • Aspirate 20-100 mL of dark, deoxygenated blood until bright red blood appears.
   • Send aspirate for blood gas to confirm ischaemia (pO₂ less than 30, pH less than 7.25).

3. Intracavernosal phenylephrine injection:

   • If aspiration alone doesn't achieve detumescence, inject 100-200 mcg phenylephrine (diluted: 1 mg in 20 mL saline).
   • Repeat every 3-5 minutes, monitoring blood pressure and heart rate (risk of hypertension, bradycardia).
   • Continue for up to 1 hour.

4. If medical therapy fails: Call urology for surgical shunt (distal shunt first—Winter or Al-Ghorab).

5. Treat underlying cause: FBC, sickle screen, drug history; involve haematology if sickle cell disease.

6. Counsel patient: ED risk ~30% at 8 hours; reassure treatment is underway to minimise damage.

Endpoint: Detumescence."

---

Question 3: Why is ischaemic priapism a surgical emergency?

Model Answer:

"Ischaemic priapism is a compartment syndrome of the penis. It's an emergency because:

1. Time-dependent smooth muscle necrosis: Venous outflow obstruction causes hypoxia and acidosis in the corpora cavernosa. After 4-6 hours, smooth muscle cells begin to undergo necrosis. By 12 hours, necrosis is significant; by 24 hours, it's extensive.

2. Irreversible fibrosis: Necrotic smooth muscle is replaced by collagen (fibrosis), which destroys the veno-occlusive mechanism needed for normal erections. This leads to permanent erectile dysfunction.

3. Direct correlation with outcomes: ED risk is less than 10% if treated within 12 hours, 50% at 12-24 hours, and > 90% after 24 hours.

Therefore, ischaemic priapism requires immediate intervention (aspiration + phenylephrine within 4-6 hours) to prevent lifelong sexual dysfunction."

---

Question 4: A sickle cell patient presents with stuttering priapism. What is your approach?

Model Answer:

"Stuttering priapism is a recurrent ischaemic priapism pattern, almost exclusively seen in sickle cell disease. Episodes are self-limiting (less than 4 hours) but increase in frequency and duration, eventually culminating in a major, prolonged ischaemic event.

Acute Episode Management:

• Analgesia, hydration, oxygen if hypoxic
• If episode persists > 4 hours: aspiration + phenylephrine as per standard protocol
• Involve haematology early

Prevention (Key Goal):

1. Pseudoephedrine: 30-60 mg nightly (α-agonist; promotes detumescence). Patient takes it before bed as stuttering episodes often occur nocturnally.
2. Hydroxyurea: Disease-modifying therapy; increases foetal haemoglobin, reduces sickling and priapism frequency.
3. Automated red cell exchange transfusion: For severe, refractory stuttering priapism; target HbS less than 30%.
4. Patient education: Recognise early episodes; seek help before they progress.

Counselling:

• Explain that stuttering priapism is a warning sign of future major episodes.
• Emphasise adherence to preventive therapy and haematology follow-up."

---

Question 5: What are the surgical options if aspiration and phenylephrine fail?

Model Answer:

"If medical therapy fails after 1 hour, surgical shunting is required. The principle is to create a fistula for venous drainage from the ischaemic corpora.

Distal Shunts (First-Line Surgical):

1. Winter Shunt: Percutaneous; large-bore needle through glans into corpus cavernosum, creating multiple fistulae. Quick, bedside, 60-70% success.
2. Al-Ghorab Shunt: Open; excise 1-2 cm disc of tunica albuginea at glans-corporal junction bilaterally. 70-80% success, more reliable than Winter.

Proximal Shunts (If Distal Shunts Fail or Prolonged Priapism > 48 Hours):

3. Quackels Shunt: Perineal approach; fistula between corpora cavernosa and corpus spongiosum. More invasive.
4. Grayhack Shunt: Saphenous vein graft between corpus cavernosum and femoral vein. Complex; requires vascular surgery expertise.

Penile Prosthesis:

• If priapism > 48-72 hours or shunts fail, immediate prosthesis insertion may be considered (prevents further fibrosis, restores function).
• Emerging evidence suggests early prosthesis (less than 2 weeks) has better outcomes than delayed (> 3 months).

I would escalate from distal → proximal → prosthesis, consulting a senior urologist or sexual medicine specialist."

---

Patient and Family Information

What is Priapism?

Priapism is a medical condition where you have a prolonged, painful erection lasting more than 4 hours that is not related to sexual arousal or activity. It is a medical emergency and requires urgent treatment to prevent permanent damage to your penis.

Why is it Urgent?

The blood trapped in your penis is not receiving fresh oxygen. After several hours, the lack of oxygen causes damage to the tissue inside the penis that is needed for normal erections. If priapism is not treated quickly (within 4-6 hours), this damage becomes permanent, and you may lose the ability to have erections in the future.

What Causes Priapism?

Common causes include:

• Sickle cell disease (the most common cause in children and young men)
• Medications, such as treatments for erectile dysfunction (injections), antidepressants (like trazodone), or antipsychotics
• Recreational drugs, such as cocaine
• Blood disorders (leukaemia, blood clotting problems)
• Injury to the pelvis or penis (can cause a different, less urgent type)
• No clear cause (in about 30-60% of cases, no cause is found)

What Will the Treatment Involve?

Step 1: Pain Relief

• You will be given strong painkillers, and a local anaesthetic injection may be used to numb the penis.

Step 2: Draining the Blood

• A doctor will use a small needle to remove the trapped blood from your penis. This helps reduce the pressure and allows fresh blood to flow in.

Step 3: Medication Injection

• If draining alone doesn't work, a medication (phenylephrine) will be injected into the penis to help the erection go down. Your blood pressure and heart rate will be monitored during this.

Step 4: Surgery (If Needed)

• If the above steps don't work, a small operation may be needed to create a "drainage channel" (called a shunt) to let the blood out. This is done under anaesthetic.

Step 5: Penile Implant (In Severe Cases)

• If priapism has lasted a very long time (more than 24-48 hours), the tissue may already be damaged. In this case, an implant (prosthesis) may be offered to allow you to have erections in the future.

What Happens Afterwards?

• If treated quickly (within 12 hours), most men recover normal erections.
• If treatment is delayed (more than 24 hours), there is a high risk of permanent erectile dysfunction (difficulty getting or keeping an erection).
• You will have follow-up appointments to check your recovery and discuss options if you have ongoing problems (such as medications, vacuum devices, or implants).

If You Have Sickle Cell Disease

• Priapism is more common in sickle cell disease.
• You may experience stuttering priapism—short episodes of painful erections that last a few hours and resolve on their own. These are warning signs of a major episode.
• What to do: If you have stuttering episodes, see your doctor. You may be given medication (such as pseudoephedrine or hydroxyurea) to prevent a major, long-lasting episode.
• Seek help immediately if an erection lasts more than 4 hours.

Resources and Support

• NHS Priapism Information: https://www.nhs.uk/conditions/priapism
• Sickle Cell Society: https://www.sicklecellsociety.org (for patients with sickle cell disease)
• Sexual Advice Association: https://www.sda.uk.net (support for erectile dysfunction)

Remember: Priapism is an emergency. If you have an erection lasting more than 4 hours, go to A&E immediately.

---

Key Guidelines and Evidence

Major Clinical Guidelines

1. American Urological Association (AUA) / Sexual Medicine Society of North America (SMSNA) Guideline on Priapism (2022)

   • Comprehensive guideline covering diagnosis, classification, and stepwise management
   • Recommends aspiration + phenylephrine as first-line; distal shunts if medical therapy fails
   • Addresses sickle cell-specific management and stuttering priapism [1]

2. European Association of Urology (EAU) Guidelines on Sexual and Reproductive Health

   • Similar recommendations; emphasises early intervention within 4-6 hours
   • Advocates for penile blood gas as gold standard diagnostic test [7]

3. International Consultation on Sexual Medicine (ICSM) Recommendations (2024)

   • Latest consensus on priapism management
   • Emerging role of early prosthesis insertion in refractory cases [17]

4. Guidelines for Management of Sickle Cell Emergencies (2025)

   • Multidisciplinary guideline covering priapism in SCD
   • Recommends exchange transfusion for refractory cases; hydroxyurea for prevention [13]

Landmark Studies and Systematic Reviews

---

References

1. Bivalacqua TJ, Allen BK, Brock GB, et al. The Diagnosis and Management of Recurrent Ischemic Priapism, Priapism in Sickle Cell Patients, and Non-Ischemic Priapism: An AUA/SMSNA Guideline. J Urol. 2022;207(4):789-802. PMID: 35536142. DOI: 10.1097/JU.0000000000002767

2. Burnett AL, Bivalacqua TJ. Priapism: current principles and practice. Urol Clin North Am. 2007;34(4):631-642. PMID: 17983901. DOI: 10.1016/j.ucl.2007.08.006

3. Halls JE, Patel DV, Walkden M, Patel U. Non-ischaemic priapism: diagnosis and management update. Br J Radiol. 2020;93(1109):20200034. PMID: 32343937. DOI: 10.1259/bjr.20200034

4. Salonia A, Eardley I, Giuliano F, et al. European Association of Urology Guidelines on Priapism. Eur Urol. 2014;65(2):480-489. PMID: 24314827. DOI: 10.1016/j.eururo.2013.11.008

5. Kavanagh PL, Fasipe TA, Wun T. Sickle Cell Disease: A Review. JAMA. 2022;328(1):57-68. PMID: 35788790. DOI: 10.1001/jama.2022.10233

6. Rourke K, Nehra A. Pharmacologic causes of priapism. Rev Urol. 2002;4(2):52-55. PMID: 16985658.

7. Montague DK, Jarow J, Broderick GA, et al. American Urological Association guideline on the management of priapism. J Urol. 2003;170(4 Pt 1):1318-1324. PMID: 14501756. DOI: 10.1097/01.ju.0000087608.07371.ca

8. Sidhu AS, Wayne GF, Kim BJ, et al. The Hemodynamic Effects of Intracavernosal Phenylephrine for the Treatment of Ischemic Priapism. J Sex Med. 2018;15(7):1003-1009. PMID: 29960632. DOI: 10.1016/j.jsxm.2018.05.012

9. Zacharakis E, Garaffa G, Raheem AA, et al. Penile prosthesis insertion in patients with refractory ischaemic priapism: early vs delayed implantation. BJU Int. 2014;114(4):576-581. PMID: 24219061. DOI: 10.1111/bju.12520

10. Adeyokunnu AA, Hendry WF. The prognosis in priapism. Br J Urol. 1980;52(4):323-326. PMID: 7426999. DOI: 10.1111/j.1464-410x.1980.tb02969.x

11. Chinegwundoh F, Anie KA. Treatments for priapism in boys and men with sickle cell disease. Cochrane Database Syst Rev. 2004;(4):CD004198. PMID: 15495088. DOI: 10.1002/14651858.CD004198.pub2

12. Idris IM, Burnett AL, DeBaun MR. Epidemiology and treatment of priapism in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2022;2022(1):562-567. PMID: 36485155. DOI: 10.1182/hematology.2022000380

13. Ballas SK, Lyon D. Safety and efficacy of blood exchange transfusion for priapism complicating sickle cell disease. J Clin Apher. 2016;31(1):5-10. PMID: 25809639. DOI: 10.1002/jca.21394

14. Broderick GA, Kadioglu A, Bivalacqua TJ, et al. Priapism: pathogenesis, epidemiology, and management. J Sex Med. 2010;7(1 Pt 2):476-500. PMID: 20092449. DOI: 10.1111/j.1743-6109.2009.01625.x

15. Altez-Fernandez C, Lamas L, Bohorquez M, et al. Cocaine-related ischemic priapism. Systematic review and presentation of a single center series. Actas Urol Esp (Engl Ed). 2024;48(4):265-271. PMID: 38369291. DOI: 10.1016/j.acuroe.2024.02.007

16. Abou Chawareb E, Hammad MAM, Barham DW, et al. Early inflatable penile prosthesis implantation offers superior outcomes compared to delayed insertion following ischemic priapism: a narrative review. Int J Impot Res. 2025;37(1):10-17. PMID: 38720138. DOI: 10.1038/s41443-024-00900-y

17. Kadioglu A, Kadihasanoglu M, Muneer A, et al. Priapism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024). Sex Med Rev. 2026 Jan 5. PMID: 41489159. DOI: 10.1093/sxmrev/qeaf072

18. Arduini GAO, Trovó de Marqui AB. Prevalence and Characteristics of Priapism in Sickle Cell Disease. Hemoglobin. 2018;42(2):73-77. PMID: 29745276. DOI: 10.1080/03630269.2018.1452760

19. Mekontso Dessap A, Dauger S, Khellaf M, et al. Guidelines for the management of emergencies and critical illness in pediatric and adult patients with sickle cell disease. Ann Intensive Care. 2025;15(1):65. PMID: 40439782. DOI: 10.1186/s13613-025-01479-3

20. Ekong A, Berg L, Amos RJ, et al. Regular automated red cell exchange transfusion in the management of stuttering priapism complicating sickle cell disease. Br J Haematol. 2018;180(2):262-265. PMID: 27723091. DOI: 10.1111/bjh.14393

---